Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes J, Azaceta G, Ibáñez M, Chen T, Notario C, Amer N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo J, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: carcelero e. Blood Adv. 2025 Jan 14;9(1):39-53. doi: 10.1182/bloodadvances.2024013648. Blood Adv. 2025. PMID: 39388660
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?
Castaño-Díez S, Álamo JR, López-Guerra M, Gómez-Hernando M, Zugasti I, Jiménez-Vicente C, Guijarro F, López-Oreja I, Esteban D, Charry P, Torrecillas V, Mont-de Torres L, Cortés-Bullich A, Bataller Á, Guardia A, Munárriz D, Carcelero E, Riu G, Triguero A, Tovar N, Vela D, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: carcelero e. Oncologist. 2024 Sep 30:oyae246. doi: 10.1093/oncolo/oyae246. Online ahead of print. Oncologist. 2024. PMID: 39349391 Free article.
Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD.
Martínez C, Carcelero E, Gutiérrez A, Sancho E, Martí-Tutusaus JM, Magnano L, Mozas P, Fernández-Avilés F, Antelo MG, Setoain X, Rodríguez S, Esteve J. Martínez C, et al. Among authors: carcelero e. Hematol Oncol. 2024 Sep;42(5):e3299. doi: 10.1002/hon.3299. Hematol Oncol. 2024. PMID: 39132926
Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation.
Escribano-Serrat S, Pedraza A, Suárez-Lledó M, Charry P, De Moner B, Martinez-Sanchez J, Ramos A, Ventosa-Capell H, Moreno C, Guardia L, Monge-Escartín I, Riu G, Carcelero E, Cid J, Lozano M, Gómez P, García E, Martín L, Carreras E, Fernández-Avilés F, Martínez C, Rovira M, Salas MQ, Díaz-Ricart M. Escribano-Serrat S, et al. Among authors: carcelero e. Bone Marrow Transplant. 2024 Oct;59(10):1466-1476. doi: 10.1038/s41409-024-02388-y. Epub 2024 Aug 8. Bone Marrow Transplant. 2024. PMID: 39117736
Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation.
Marco DN, Molina M, Guio AM, Julian J, Fortuna V, Fabregat-Zaragoza VL, Salas MQ, Monge-Escartín I, Riu-Viladoms G, Carcelero E, Roma JR, Llobet N, Arcarons J, Suárez-Lledó M, Rosiñol L, Fernández-Avilés F, Rovira M, Brunet M, Martínez C. Marco DN, et al. Among authors: carcelero e. Pharmaceuticals (Basel). 2024 Apr 25;17(5):553. doi: 10.3390/ph17050553. Pharmaceuticals (Basel). 2024. PMID: 38794124 Free PMC article.
At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program.
Ruiz-Boy S, Pedraza A, Prat M, Salas MQ, Carcelero E, Riu-Viladoms G, Suárez-Lledó M, Monge-Escartín I, Rodríguez-Lobato LG, Martínez-Roca A, Rovira M, Martínez C, Gallego C, Urbano-Ispizua Á, Sánchez J, Marcos MÁ, Fernández-Avilés F. Ruiz-Boy S, et al. Among authors: carcelero e. Pharmaceuticals (Basel). 2023 Dec 18;16(12):1741. doi: 10.3390/ph16121741. Pharmaceuticals (Basel). 2023. PMID: 38139867 Free PMC article.
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Brusosa M, Ruiz S, Monge I, Solano MT, Rosiñol L, Esteve J, Carreras E, Marcos MÁ, Riu G, Carcelero E, Martinez C, Fernández-Avilés F, Rovira M, Suárez-Lledó M, Salas MQ. Brusosa M, et al. Among authors: carcelero e. Ann Hematol. 2024 Feb;103(2):609-621. doi: 10.1007/s00277-023-05542-6. Epub 2023 Nov 14. Ann Hematol. 2024. PMID: 37957371
Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide.
Marco DN, Salas MQ, Gutiérrez-García G, Monge I, Riu G, Carcelero E, Roma JR, Llobet N, Arcarons J, Suárez-Lledó M, Martínez N, Pedraza A, Domenech A, Rosiñol L, Fernández-Avilés F, Urbano-Ispízua Á, Rovira M, Brunet M, Martínez C. Marco DN, et al. Among authors: carcelero e. Pharmaceuticals (Basel). 2022 Dec 9;15(12):1529. doi: 10.3390/ph15121529. Pharmaceuticals (Basel). 2022. PMID: 36558980 Free PMC article.
Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation.
Gómez-Hernando M, Quintana LF, Suárez-Lledo M, Martínez-Cibrian N, Rivero A, Ruiz-Boy S, Carcelero E, Mate P, Riu G, Monge I, Serrahima A, Solano MT, Rosiñol L, Esteve J, Urbano-Ispizua A, Carreras E, Fernández-Avilés F, Martínez C, Rovira M, Salas MQ. Gómez-Hernando M, et al. Among authors: carcelero e. Bone Marrow Transplant. 2023 Feb;58(2):212-214. doi: 10.1038/s41409-022-01864-7. Epub 2022 Nov 5. Bone Marrow Transplant. 2023. PMID: 36335256 No abstract available.
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
Brasó-Maristany F, Sansó M, Chic N, Martínez D, González-Farré B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sánchez M, Soy D, Jares P, Peg V, Saura C, Muñoz M, Prat A, Vivancos A. Brasó-Maristany F, et al. Among authors: carcelero e. Front Oncol. 2021 Sep 20;11:710596. doi: 10.3389/fonc.2021.710596. eCollection 2021. Front Oncol. 2021. PMID: 34616675 Free PMC article.
21 results